Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
24.57
-0.36 (-1.44%)
At close: Aug 26, 2026, 4:00 PM EDT
24.35
-0.22 (-0.90%)
After-hours: Aug 26, 2026, 5:20 PM EDT

Denali Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
3.6--330.53108.4648.66
Revenue Growth
---204.74%122.89%-85.50%
Gross Profit
-397.21-418.78-396.44-93.35-250.27-216.69
Operating Income
-541.95-555.34-501.88-196.7-340.74-295.75
Net Income
-511.45-512.54-422.77-145.22-325.99-290.58
Earnings Per Share
-2.83-2.97-2.57-1.06-2.60-2.39
EPS Growth
------

Revenue by Segment

Fiscal YearTTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingSep '23 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Takeda Collaboration
-1051.9229.9227.165.93
Sanofi Collaboration
-2553.4151.0720.75
Biogen Collaboration
295.79295.533.153.74307.44-
Revenue (Total)
-330.53----

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
940.01966.21,1921,0351,3361,291
Total Debt
37.6942.2954.3252.2460.3564.01
Net Cash (Debt)
902.32923.911,137982.271,2761,227
Net Cash Growth
-2.92%-18.77%15.79%-23.01%4.00%-14.42%
Net Cash Per Share
5.005.356.927.1510.1610.10

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-434.04-412.6-347.69-357.99-244.72-211.39
Capital Expenditures
-3.42-9.5-15.91-12.94-17.83-8.5
Free Cash Flow
-437.46-422.1-363.61-370.93-262.55-219.89
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
----28.24%-230.74%-
Operating Margin
-15037.38%---59.51%-314.16%-607.78%
Pretax Margin
-14188.37%---43.93%-300.54%-598.34%
Profit Margin
-14191.20%---43.94%-300.56%-597.15%
FCF Margin
-12138.10%---112.22%-242.06%-451.88%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-46.4646.4646.4646.4646.46
PS Ratio
1092.85--8.9734.82111.93